ArticleHealth affairs (Project Hope)2024
Estimating The Impact Of Out-Of-Pocket Cost Changes On Abandonment Of HIV Pre-Exposure Prophylaxis.
Article in Health affairs (Project Hope), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Free antiretrovirals as a key tool against the HIV pandemic: A systematic review.HIV medicine · 2025Pooled it
- Applying Behavioral Economics to HIV Prevention: Development of a Novel PrEP Demand Task.AIDS and behavior · 2026Article
- Evolving drivers of preexposure prophylaxis discontinuation among US MSM, 2018-2024.AIDS (London, England) · 2026Article
- Modelling the 5-Year Impact of Twice-Yearly Injectable Lenacapavir for HIV Pre-Exposure Prophylaxis in the United States.Journal of the International AIDS Society · 2026Article
- Preventive service use among Medicaid expansion adults, 2014-2019.Health affairs scholar · 2026Article
- What should infectious diseases clinicians know about pharmacy benefit managers and their impact on our patients?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Review
- Expanding Pharmacists' Prescribing Authority and Medication Uptake: Evidence From Pre-Exposure Prophylaxis.AJPM focus · 2025Article
- Preexposure Prophylaxis Prescription Dispensation Status and HIV-1 Acquisition.JAMA network open · 2025Observational
- Anticipated Out-Of-Pocket Costs and Prostate Cancer Management Among Men With Commercial Insurance.Cancer medicine · 2025Article
- Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions.The Journal of allergy and clinical immunology · 2025Article
- Why is roll-out of long-acting PrEP agents so slow?Current opinion in HIV and AIDS · 2025Review
- Perceived Versus Actual Costs of HIV Pre-Exposure Prophylaxis Among Gay, Bisexual, and Other Men Who Have Sex with Men in the United States.AIDS patient care and STDs · 2024Article
- Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?Journal of health economics and outcomes research · 2024Article
- Health Care Providers' Experiences With and Perceived Barriers to Implementation of Long-Acting Injectable HIV Preexposure Prophylaxis: A Cross-Sectional Survey.Journal of the International Association of Providers of AIDS CareArticle
- Preferences for PrEP program attributes among Black women aged ⩾45 in the US South: A secondary analysis using discrete choice experiment.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Oral HIV pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV. Several different developments in the US either threaten to increase or promise to decrease PrEP out-of-pocket costs and access in the coming years. In a sample of 58,529 people with a new insurer-approved PrEP prescription, we estimated risk-adjusted percentages of patients who abandoned (did not fill) their initial prescription across six out-of-pocket cost categories. We then simulated the percentage of patients who would abandon PrEP under hypothetical changes to out-of-pocket costs, ranging from $0 to more than $500. PrEP abandonment rates of 5.5 percent at $0 rose to 42.6 percent at more than $500; even a small increase from $0 to $10 doubled the rate of abandonment. Conversely, abandonment rates that were 48.0 percent with out-of-pocket costs of more than $500 dropped to 7.3 percent when those costs were cut to $0. HIV diagnoses were two to three times higher among patients who abandoned PrEP prescriptions than among those who filled them. These results imply that recent legal challenges to the provision of PrEP with no cost sharing could substantially increase PrEP abandonment and HIV rates, upending progress on the HIV/AIDS epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.